Core Viewpoint - Medtronic's diabetes care subsidiary, MiniMed Group, is initiating an IPO to become an independent entity on Nasdaq, offering approximately 28 million shares at an expected price range of $25 to $28 per share [1][2]. Group 1: IPO Details - MiniMed Group will trade under the ticker MMED and aims to raise funds to strengthen its balance sheet and cover general expenses [1][2]. - Post-IPO, Medtronic will retain 89% to 90% ownership of MiniMed Group, allowing for separate valuation of its diabetes portfolio and other business segments [2]. Group 2: Company Performance - Medtronic's stock has underperformed with a one-year performance of 4.6%, compared to the Vanguard Health Care Index Fund ETF's return of 7.99% [4]. - The company offers a dividend yield of 2.88%, appealing to income investors despite the performance trade-off [4][5]. Group 3: Valuation and Growth - Medtronic's stock trades at a forward P/E ratio of 23.29x, which is a moderate discount to its five-year average P/E of 25.18x, indicating stable growth prospects [5]. - The company is projected to grow profits by 7.95% in 2027, 7.74% in 2028, and 8.18% in 2029, with a payout ratio of 50% supporting continued dividend payments [5].